Navigation Links
Potent Hepatitis C Virus Inhibitors Show Efficacy and Potential for Once Daily Dosing in Preclinical Studies
Date:11/1/2007

Data Presented at the 2nd Annual International Workshop on Hepatitis C

Resistance & New Compounds

WATERTOWN, Mass., Nov. 1 /PRNewswire/ -- Researchers from Enanta Pharmaceuticals today presented data on novel Hepatitis C protease inhibitors with potent antiviral activity in the cell-based replicon assay and favorable pre-clinical pharmacokinetic properties with the potential for once-daily dosing in humans.

The hepatitis C virus (HCV) increases a person's chances of developing chronic liver disease, and affects more than 170 million people worldwide. Current treatment options are not sufficient. Specifically targeted antiviral therapies for HCV, such as NS3/4a protease inhibitors, may have the potential to increase the proportion of patients in whom the virus can be eradicated.

The abstract, "Potent HCV protease inhibitors with the potential for once-daily dosing," was presented today in a session focused on protease inhibitors at 8:30 a.m. during the 2nd Annual International Workshop on Hepatitis C Resistance & New Compounds in Boston.

"These compounds have demonstrated remarkable potency in the antiviral replicon assay and favorable pre-clinical pharmacokinetic properties supporting the potential for once-daily dosing in humans," said Yat Sun Or, Senior Vice President, Research and Development of Enanta Pharmaceuticals. "These data demonstrate our commitment to the discovery of next-generation protease inhibitors that will enhance the treatment options for patients who are infected with hepatitis C."

Abbott and Enanta Pharmaceuticals formed a collaboration in 2006 to develop and commercialize HCV protease inhibitors. The partnership leverages Abbott's innovative work in the protease inhibitor field against the Human Immunodeficiency Virus (HIV) and leadership in the area of antiviral therapies and Enanta's core expertise in chemistry and drug discovery. The HCV NS 3/4A serine protease is the focus of
'/>"/>

SOURCE Enanta Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. New Information on the Potential of Plasmin Shared at ISTH Congress
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
5. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
6. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
7. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
8. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
9. Expert Opinion Highlights Avigens AV411 as Potential New Therapeutic for Neuropathic Pain and Opioid Withdrawal
10. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
11. New Study Shows That telmisartan has Greater Renoprotective Potential Thanlosartan in Hypertensive Patients With Type 2 Diabetes

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)... , PLEASANTON, Calif., Dec. 2 /PRNewswire-Firs...nced today that the United States Food & Drug ...ed use for its licensed nucleic acid test, to scre...dividual donations. The test, called the cobas... system, is a qualitative, in-vitro test for the s...
(Date:12/2/2009)... , NANJING, China, Dec. 2 /PRNewswire-...r the "Company") (NYSE: SCR ), a leading pharmac...anufacturing, and marketing of branded,generic and...ted that its,subsidiary Jiangsu Yanshen Biological...s suspended production of all its products in orde...
(Date:12/2/2009)... , EAST HANOVER, N.J., Dec. 2 /PRNewsw...cluding a late-breaking presentation on Tasigna...ic myeloid leukemia, demonstrate the strength of t... care of patients. ,, The new data, at the 51s...ing and Exposition, highlight the company,s curren...
Breaking Medicine Technology:FDA Approves Use of Roche Test to Screen Source Plasma for HIV, Hepatitis B Virus and Hepatitis C Virus 2FDA Approves Use of Roche Test to Screen Source Plasma for HIV, Hepatitis B Virus and Hepatitis C Virus 3Simcere Pharmaceutical Group Announces Jiangsu Yanshen's Voluntary Suspension of Production 2Simcere Pharmaceutical Group Announces Jiangsu Yanshen's Voluntary Suspension of Production 3Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 2Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 3Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 4Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 5Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 7Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 8Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 9Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 10Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 11Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 12Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 13Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 14Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 15Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 16Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 17Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 18Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 19Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 20Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 21Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 22Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 23Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 24Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 25Brain computer interface developed at Brown begins new clinical trial 8783 1Brain computer interface developed at Brown begins new clinical trial 8783 2Brain computer interface developed at Brown begins new clinical trial 8783 3Brain computer interface developed at Brown begins new clinical trial 8783 4Published Study Shows VNUS ClosureFAST 26amp 3B 238482 3B System Significantly Superior to Laser for Varicose Vein Treatment 48411 1Published Study Shows VNUS ClosureFAST 26amp 3B 238482 3B System Significantly Superior to Laser for Varicose Vein Treatment 48411 2Published Study Shows VNUS ClosureFAST 26amp 3B 238482 3B System Significantly Superior to Laser for Varicose Vein Treatment 48411 3Forterus Inc Announces Special Board Meeting 3B Nominates Jeff Walton Former Bear Stearns President to Board of Directors 48408 1Forterus Inc Announces Special Board Meeting 3B Nominates Jeff Walton Former Bear Stearns President to Board of Directors 48408 2
...nces announced,today, the initiation of a Phase 2 ...he treatment and management of acute infectious,mo...apeutics for the,treatment for this debilitating c...n-Barr virus (EBV), "Valomaciclovir has shown a b...ibition of viral replication of herpes zoster and ...
...gel,Pharmaceuticals, Inc. (Nasdaq: RIGL ) today a... PFE ), has begun a Phase 1 clinical trial of an,...kinase inhibitor, R343,for the treatment of allerg...Rigel,s clinical portfolio., Under the terms of t...will receive a $5 million milestone payment from P...
Other Medicine Technology:Epiphany Biosciences Reports Initiation of Phase 2 Study of Valomaciclovir for the Treatment of Acute Infectious Mononucleosis 2Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer 2Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer 3
(Date:12/2/2009)...Constraint-induced movement therapy (CIMT) is a po...ren with hemiplegic cerebral palsy, but more resea...w published in the November issue of Physical The...n Physical Therapy Association (APTA). The review,...ematic reviews, concluded that further research sh...
(Date:12/2/2009)... Revolutionary new cell phones that direct ...l be available in early 2010 from Aerius Internati...mber 2, 2009 -- Revolutionary new cell phones that...sers will be available in early 2010 from Aerius I...red with a Green Technology Award in wireless comm...
(Date:12/2/2009)... A team of Kendall Hunt authors earned the ...d at the recent National Association for Gifted Ch...ember 5-7, 2009. , Dubuqu...l Hunt authors earned the 2009 Gifted Child Quarte... Association for Gifted Children’s annual co...
(Date:12/2/2009)...HINGTON, Dec. 2 Pro-abo..., December 2 in their campaign against the U.S. Ho... Americans United for Life President and CEO Charm...the abortion lobby,s effort to expand taxpayer fun...h health care, the feminist groups and the abortio...
(Date:12/2/2009)...S ANGELES, Dec. 2 At a ...Tourism ministerial delegates came together to out...equired to give it the necessary thrust. Organized...edicaltourismassociation.com , the high-powered co...iscussed the opportunities and requests for assist...
Breaking Medicine News(10 mins):Health News:Report shows CIMT may improve arm use in children with hemiplegic cerebral palsy 2Health News:New AERIUS Cell Phones Direct Microwave Signals Away from Users 2Health News:Kendall Hunt Authors Earn NAGC “Paper of the Year” Award 2Health News:Ministerial Roundtable Discusses Future of Medical Tourism 2Health News:Ministerial Roundtable Discusses Future of Medical Tourism 3
...A hospital in Chennai has created history by succe...ant in an eight-year-old Ugandan boy using the co...on of what the procedure would cost internationall...ht to the Apollo Specialty Hospital here. ...
...Three gene variants in the DNA of 486 AIDS patient...the HIV virus, according to research published Th... will lead to a vaccine that would boost the prote...mising, the scientists said in a study to appear i...
...A British woman will be aiming to raise awareness ...y when she sets out on a solo row across the Pacif...Roz Savage, 38, has already traversed the Atlantic... across the vast expanse of the Pacific. S...
...Madrid is the culinary melting pot of a country wh...rld by the New York Times, the author of a new boo...here is no real Madrid cooking but that's because ...novative cooking in Madrid). Rincon came u...
...Supermodel Petra Nemcova turned vegetarian to help...gave up meat and dairy products in February after ... "I read that if we fish the way we fish, ... star insisted that that she felt a 'strong connec...
...Burlesque star Dita Von Teese says that she often ... healthy hobby to be a voyeur. The estran...ur pornography has something to offer to almost ev... She insists that she is just like other people ...
Other Medicine News:Health News:Chennai Hospital Conducts Bone Marrow Transplantation Successfully 2Health News:Three Gene Variants Could Hold Key for HIV Vaccine: Study 2Health News:Briton Set for Pacific Solo Odyssey to Highlight Warming 2
Alloclassic Hip
Perfecta RS Stems
S-ROM Femoral Stems - XX-Long Length Stems 36mm Neck with 21mm Calcar Replacement + Lat Neck
S-ROM Femoral Stems - Long Length Stems Standard 36mm Neck
Medicine Products: